Horsham, United Kingdom

Andrew Douglas Baxter

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Exonate Limited, Trinity College Dublin, University College Dublin. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Douglas Baxter. Retrieved from https://idiyas.com/inventor/andrew-douglas-baxter-4x8nh1rc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 6 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • West Sussex, GB (2016 - 2017)
  • Horsham, GB (2018 - 2024)

Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Andrew Douglas Baxter

Introduction

Andrew Douglas Baxter is a notable inventor based in Horsham, GB. He has made significant contributions to the field of anti-angiogenic treatments, with a focus on various medical conditions. Baxter holds a total of 6 patents, showcasing his innovative approach to addressing complex health issues.

Latest Patents

Baxter's latest patents include advancements in SRPK1 inhibitors, which are designed for anti-angiogenic treatments. These treatments target conditions such as ocular neovascularization and cancer, as well as hyperpermeability disorders, neuropathic and neurodegenerative disorders, and pain management. Additionally, he has developed methods for treating or preventing fibrosis and compounds for use in these methods. Another significant patent involves 1-methyl-1H-pyrazol-3-yl derivatives, which are aimed at treating neovascular diseases. This patent focuses on anti-angiogenic treatments and compounds that address conditions associated with abnormal angiogenesis or the over-production of pro-angiogenic VEGFxxx isoforms in the eye.

Career Highlights

Throughout his career, Baxter has worked with esteemed institutions such as University College Dublin and Exonate Limited. His work has been instrumental in advancing medical treatments that improve patient outcomes.

Collaborations

Baxter has collaborated with notable colleagues, including Breandan Kennedy and Alison Reynolds. Their combined expertise has contributed to the success of various projects and innovations.

Conclusion

Andrew Douglas Baxter's contributions to the field of anti-angiogenic treatments highlight his dedication to innovation in medicine. His patents reflect a commitment to addressing critical health challenges through scientific advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…